Saturday 17 October 2026
Export LIPO’s income statement to Excel — free account
Lipella Pharmaceuticals Inc.
LIPO Healthcare Biotechnology
Lipella Pharmaceuticals Inc.’s revenue for fiscal 2024 (year ended December 2024) was $536,400.00, up 19.3% from fiscal 2023. In the quarter to September 2025, revenue fell 36.4%, EPS grew 78.3% and free cash flow fell 41.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
0.00
0.00
NaN
Follow LIPO
| Sep '25 | Jun '25 | Mar '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | 7.97 | 9.93 | 5.96 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (2.61) | (3.62) | (3.23) | |
P/B ratio |
— | 1.37 | 1.27 | 1.67 | |
Price to Tangible BV |
— | 1.37 | 1.27 | 1.67 | |
EV/Sales |
— | 2.69 | 2.38 | 2.45 | |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
— | (0.28) | (0.31) | (0.33) | |
EV/FCF |
— | (0.28) | (0.31) | (0.33) | |
Quick Ratio |
2.89 | 3.78 | 5.55 | 3.01 | |
Current Ratio |
3.24 | 4.60 | 6.21 | 3.47 | |
Net Debt/EBITDA |
1.46 | 2.05 | 3.18 | 1.51 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.16 | 0.13 | 0.17 | |
Operating CF/Net income |
0.74 | 1.08 | 1.09 | 0.69 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 913.03% | 767.77% | 611.57% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 751.67% | 358.35% | 323.89% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 46.46% | |
Graham Net Nets |
— | 0.66 | 0.78 | 0.58 | |
Graham Number |
— | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
— | (394.25%) | (162.55%) | (154.75%) | |
Free Cash Flow Yield |
— | (120.61%) | (77.53%) | (124.05%) | |
Revenue per Share |
0.00 | 0.02 | 0.06 | 0.17 | |
Operating CF per Share |
(0.20) | (0.33) | (0.69) | (0.94) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.20) | (0.33) | (0.69) | (0.94) | |
Cash per Share |
0.41 | 0.65 | 2.05 | 2.08 | |
Shareholders Equity per Share |
0.33 | 0.64 | 1.98 | 1.83 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.33 | 0.64 | 1.98 | 1.83 | |
Free Cash Flow |
(0.93) | (1.43) | (1.43) | (0.99) | |
Working Capital |
1.44 | 2.69 | 4.05 | 1.86 | |
Net Current Asset Value |
1.22 | 2.46 | 4.05 | 1.86 | |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 0.04 | 0.08 | 0.06 | |
Average Payables |
0.46 | 0.39 | 0.34 | 0.26 | |
Average Assets |
2.25 | 2.95 | 4.00 | 3.13 | |
Average Common Equity |
1.47 | 2.22 | 3.32 | 2.53 |
Columns are period end dates